Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 1Phase 2 Interventional

TLK286 in Combination With Paraplatin (Carboplatin) in Recurrent Ovarian Cancer

ClinicalTrials.gov ID: NCT00051948

Public ClinicalTrials.gov record NCT00051948. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 3:00 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase 1-2a Dose-Ranging Study of TLK286 in Combination With Paraplatin (Carboplatin) in Recurrent Ovarian Cancer

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a dose-ranging, open label, Phase 1-2a study of TLK286 in combination with Paraplatin (carboplatin) in patients with recurrent ovarian cancer.

Study identification

NCT ID
NCT00051948
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1, Phase 2
Lead sponsor
Telik
Industry
Enrollment
28 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 2003 (Type not available)
Primary completion
Jan 2005 (Actual)
Completion
Jan 2005 (Actual)
Last update posted
Jul 25, 2011

2003 – 2005

United States locations

U.S. sites
6
U.S. states
4
U.S. cities
4
Facility City State ZIP Site status
Santa Monica Hematology/Oncology Consultants Santa Monica California 90404 —
Midwest Cancer Research Group, Inc. Skokie Illinois 60077 —
Beth Israel Deaconess Medical Center Boston Massachusetts 02115 —
Dana Farber Cancer Institute Boston Massachusetts 02215 —
Massachusetts General Hospital Boston Massachusetts 02215 —
M.D. Anderson Cancer Center Houston Texas 77030 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00051948, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 25, 2011 · Synced Oct 30, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00051948 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →